Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice.

By A. Daugherty, Michael W. Manning, L. Cassis. Journal of Clinical Investigation, 2000

1,404 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Immunology, Surgery

View Paper: https://www.semanticscholar.org/paper/c9fc718b0c159b7dc2591be3ae65e5594a36a37b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Thomas Braun
2. Aldons J. Lusis
3. K. Griendling
4. P. Mehta
5. S. Dikalov

In Immunology

1. P. Mehta
2. Aldons J. Lusis
3. Irving L. Weissman
4. K. Griendling
5. Rhian M. Touyz
6. E. Schiffrin
7. S. Dikalov

In Surgery

1. K. Griendling
2. P. Mehta

Citations in the corpus

• Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. (2007, background): “Conversely, ANG II infusion increases aortic atherosclerosis and aneurysm formation, independent of blood pressure (33).”
• Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. (2009, background): “The massive enhancement of angiotensin II signaling due to the increased expression of ACE will certainly contribute to this process, since increased levels of angiotensin II have been shown to promote atherosclerotic lesions in apoE-deficient mice (43).”
• CD47 blocking antibodies restore phagocytosis and prevent atherosclerosis (2016, methodology): “…this defect could be exploited as a translational target for cardiovascular disease, we treated a cohort of atheroprone animals (apolipoprotein-E-deficient ( apoE − / − ) mice implanted with angiotensin-II-infusing minipumps 19 ) with an inhibitory antibody directed against CD47 (Extended Data Fig.”